Table 1.
Characteristics of enrolled patients who entered the acute phase and their treatments
| Acupressure (N=83) |
Sham (N=82) |
All patients (N=165) |
|
|---|---|---|---|
|
| |||
| Patient Characteristics at Enrollment | |||
|
| |||
| Sex (Male:Female; N) | 46:37 | 50:32 | 96:69 |
|
| |||
| Mean Age (yrs; SD) | 12.5(4.3) | 12.9(4.2) | 12.7(4.2) |
|
| |||
| Race (White:Other; N) | 53:30 | 56:26 | 109:56 |
|
| |||
| Diagnosis (N): | |||
| Osteosarcoma: | 16 (19%) | 17 (21%) | 33 |
| Hodgkin Lymphoma: | 20 (24%) | 29 (35%) | 49 |
| Ewings sarcoma: | 9 (11%) | 6 (7%) | 15 |
| Other: | 38 (46%) | 30 (37%) | 68 |
|
| |||
| Chemotherapy-Naive (N) | 81 (98%) | 78 (95%) | 159 |
|
| |||
| Treatment Characteristics | |||
|
| |||
| Median Duration of Acute Phase (days; interquartile range) | 4 (3–5) | 4 (3–4) | 4 (3–4) |
| Duration of Acute Phase (N) | |||
| 1-day | 2 | 3 | 5 |
| 2-day | 10 | 15 | 25 |
| 3-day | 21 | 21 | 42 |
| 4-day | 27 | 30 | 57 |
| 5-day | 11 | 5 | 16 |
| 6-day | 7 | 4 | 11 |
| 7-day | 5 | 4 | 9 |
|
| |||
| Chemotherapy Agents Received (N) | |||
| cisplatin ≥ 50 mg/m2/dose: | 33 (40%) | 31 (38%) | 64 |
| cyclophosphamide + anthracycline: | 38 (46%) | 40 (39%) | 78 |
| ifosfamide + anthracycline: | 12 (14%) | 11 (13%) | 23 |
|
| |||
| Antiemetics Received for Prophylaxis (N) | |||
| ondansetron/granisetron: | 39 (47%) | 32 (39%) | 71 |
| ondansetron/granisetron + dexamethasone: | 22 (27%) | 25 (30%) | 47 |
| ondansetron/granisetron, dexamethasone + aprepitant: | 22 (27%) | 25 (30%) | 47 |
N: number of patients; SD: standard deviation. Percentages may not total 100% because of rounding.